SKIN-STIM CLINICAL REGISTRY STUDY PROTOCOL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

The study will enroll and treat a patients to assess improvement in the appearance of facial wrinkles utilizing a bioelectric or biologics (PRF + amniotic fluid) therapy or a combination of bioelectric and biologics therapy.

The study will enroll and treat a minimum of 49 subjects (23 in treatment Group A receiving a bioelectric treatment alone, 23 in treatment Group B receiving biologics treatment alone and 23 in Group C receiving combined bioelectric + biologics treatment) with moderate facial wrinkles corresponding to a grade of 4-6 on the validated Fitzpatrick Wrinkle Assessment Scale.

Subject photos will be evaluated using the 9-point Fitzpatrick Wrinkle Assessment Scale at all follow up visits. An improvement is noted by a decrease in the numeric Fitzpatrick Wrinkle score. The Fitzpatrick Wrinkle Assessment ranges from 1-9. Wrinkle Score between baseline and 90 days post treatment assessment. Positive values indicates an increase in score, while negative values indicate a decrease

Adverse Events [ Time Frame: 90 days post treatment ]

The rate of adverse events occurring in treatment subjects will be assessed.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

35 Years to 60 Years (Adult)

Sexes Eligible for Study:

Female or Male

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Females 35-60 years of age with Fitzpatrick Skin Color Type I-IV.

Subjects with clinical evidence of facial wrinkles mild to moderate in severity as specified by a grade 4-6 on the Fitzpatrick Wrinkle Assessment Scale.

Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.

Willingness and ability to provide written photo consent and adherence to photography procedures (i.e., removal of jewelry and makeup).

Willingness and ability to provide written informed consent prior to performance of any study related procedure.

Exclusion Criteria:

Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a reliable form of birth control.

Subjects who have had prior exposure to any hyaluronic acid, or any other filler, injection for any purpose in the 12 months preceding study enrollment through the duration of the study.

Subjects who have had prior exposure to any botulinum toxin for facial rhytids in the 6 months preceding study enrollment through the duration of the study.

Subjects who have had a prior cosmetic procedure to improve facial rhytids (i.e., rhytidectomy, periorbital or eyelid/eyebrow surgery, brow lift, CO2/erbium laser resurfacing, Thermage/Thermacool radiofrequency treatment) within 12 months or who have visible scars that may affect evaluation of response and/or quality of photography.

Ablative skin resurfacing on the glabellar area within the previous 6 months or during the study.

Retinoid, microdermabrasion, or prescription level glycolic acid treatments within 3 months prior to study participation or during the study.

Active cut, wound, or infection on the skin.

Oral Isotretinon within the past 12 months.

Active HSV-1.

History of keloids or hypertrophic scarring.

Existing or history of skin malignancy.

Any existing skin disease.

History of collagen or vascular disease.

Subjects who have implantable pacemaker, automatic implantable defibrillator/ cadioversor (AICD), or any other implantable electric device.

Subjects who have used, within 30 days, any medication that can cause dermal hypersensitivity or affect skin characteristics.

History of autoimmune disease.

History of any disease that inhibits pain sensation.

History of Diabetes I or II.

Concurrent therapy that, in the investigator’s opinion, would interfere with the evaluation of the safety or efficacy of the study medication.

Subjects who anticipate the need for surgery or overnight hospitalization during the study.

Subjects who, in the Investigator’s opinion, have a history of poor cooperation, non¬compliance with medical treatment or unreliability.

Enrollment in any active study involving the use of investigational devices or drugs.

Patients diagnosed with skin or any other form of cancer.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01299103